Francisco Casquero Ocio-rekin lankidetzan egindako argitalpenak (7)

2021

  1. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: Toxicity, prostatespecific antigen kinetics, and cancer control

    Journal of Contemporary Brachytherapy, Vol. 13, Núm. 1, pp. 12-17

2020

  1. MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?

    Clinical and Translational Radiation Oncology, Vol. 24, pp. 135-139

  2. Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial

    Radiotherapy and Oncology, Vol. 146, pp. 16-20

2019

  1. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study

    Radiotherapy and Oncology, Vol. 135, pp. 13-18

2018

  1. Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial

    Radiotherapy and Oncology, Vol. 126, Núm. 2, pp. 278-282

2016

  1. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial

    Radiotherapy and Oncology, Vol. 119, Núm. 1, pp. 91-96

2014

  1. Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy

    Journal of Contemporary Brachytherapy, Vol. 6, Núm. 2, pp. 154-160